NEW YORK (GenomeWeb News) – Vermillion has tapped Thomas McLain to be president and CEO, replacing interim CEO Bruce Huebner, who will retain his position as a company director.

McLain formerly was CEO and CFO of Claro Scientific, an early-stage diagnostic company, and he held senior management positions at Nabi Biopharmaceuticals and was a member of the board of the Biotechnology Industry Organization.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.